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 Summary
 Background:  Vacuum-assisted breast biopsy / Mammotome HH ® Breast Biopsy System/ is the milestone in the 
diagnosis of breast lesions. This system has proven to be as diagnostically reliable as open surgery, 
but without scarring, deformations and hospitalizations associated with an open procedure. The 
aim of our study was to assess the role and possibilities of using this biopsy in treatment of benign 
breast lesions like fibroadenoma.
 Material/Methods:  From 2001 to 2004, about 1118 Mammotome biopsies were performed in our Department. Among 
445 Mammotome biopsies performed under US control there were 211 cases of fibroadenomas. 
Follow-up was performed in 156 patients with this result at 6 and 12 months after biopsy. In our 
study we took into considerations the size, localizations as well as performers.
 Results: In 2002 there were 70.8% patients with total lesion excision, 16.7% with residual lesion and 12.5% 
women with hematomas or scars. In 2003-2004 there were more women with total lesion excision 
(84.3%), fewer residual tumors and other lesions.
 Conclusions:  In future, Mammotome breast biopsy can replace scalpel, and will become an alternative method to 
open surgical excision of fibroadenomas. It is important especially in the cases of young women to 
prevent cosmetic deformations and scars.
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Background
Introduction of mammotome biopsy in 1995 was a milesto-
ne in diagnostics of impalpable breast lesions. Combining 
all the types of biopsy methods used to date, this technique 
is currently the most modern form of low-invasive diagno-
stics, allowing to avoid unnecessary surgical procedures.
Special design of the needle, including a „aperture” of dif-
ferent sizes, knife with rotational drive and vacuum assis-
tance facilitates collection of pathologic lesion specimens. 
The procedure is performed under USG or digital mam-
mography control, which allows to monitor the course of 
the procedure continuously. Size of the specimens, possi-
bility of needle rotation in the desired direction, aspiration 
of blood appearing at the biopsy site, guarantee obtaining 
representative diagnostic material as a result of the pro-
cedure. In comparison with other biopsy types, the tech-
nique is characterized by the highest sensitivity and speci-
ficity [1–5].
Up to the recent times, mammotome biopsy was applied 
exclusively for diagnostic purposes. However, attempts to 
use this technique to remove benign lesions of the breast 
have been undertaken for many years. In 2006, U.S. Food 
and Drug Administration and the National Institute of 
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Health and Clinical Excellence included mammotome biop-
sy in the group of therapeutic procedures used for resection 
of benign tumors [6–8].
Aim of the study
In our Laboratory, since the time of introduction of mam-
motome biopsy, indications for the procedure have included 
complete resection of fibroadenoma type lesions. The aim 
of the study was to assess the effectiveness of the method 
as a therapeutic procedure.
Materials and methods
In 2001–2004, 1118 USG- and MGR-guided mammotome 
biopsies were performed. Stereotaxic biopsies were per-
formed in 573 patients, USG-guided ones in a total of 445 
cases including 211 with histopathologically confirmed 
fibroadenoma type lesions. Only the patients in whom evi-
dent characteristics of fibroadenomas were determined 
either in USG, or MGR, or both, were qualified for comple-
te resection of the lesions. The group included also some 
patients with “palpable” lesions who did not want open 
surgery. The biopsies were performed by two specialists – a 
surgeon-oncologists and a radiologist. USG-guided proce-
dures were performed using a Kretz apparatus with linear 
7.5–10 MHz head and Mammotome HH manufactured by 
Johnson&Johnson.
After localization of the lesion by USG and inducing local 
anesthesia with 1 % Xylocaine, the biopsy needle was 
introduced into the breast through a small cutanepus 
incision, a few millimeters long, so as to obtain the most 
convenient position of the aperture, i.e. below the lesion. 
In case of difficult localizations, parasternal or inter-
costal, the needle was inserted with lateral approach for 
safety considerations (risk of disrupting the integrity of 
the thoracic wall). The needle gauge was determined by 
the tumor size and equipment availability (8G needle 
– aperture of 23 mm length, bioptate diameter 3.35 mm, 
11G needle – 19.4 mm and 2.16 mm, respectively). After 
starting the vacuum-assisted drive mechanism the lesion 
was aspirated into the biopsy chamber and the „sleeve” 
knife cut a fragment of it. The same suction mechanism 
propelled the bioptate out of the needle. The biopsies were 
collected in a fan-like or clock-like pattern. The procedure 
was repeated until the last lesion fragments visible under 
USG were removed. Before the completion of the procedure 
and additional harvesting “round” was performed despite 
no visible abnormalities, for radicalization of the resection 
procedure (Figure 1). The tissue material was placed in 10% 
Formalin solution and sent to the histopathology labora-
tory. After completion of the procedure and needle with-
drawal, the cutaneous incision was covered with sterile 
dressing and pressure was provided by elastic bandage. The 
patient returned home after the procedure. The total time 
was ca. 20 minutes (Figures 2 and 3 a, b).
The post-biopsy follow-up schedule included physical exa-
mination one month after the procedure, as well as control 
USG after 6 and 12 months.
The analyzed group consisted of 155 patients. The rema-
ining 56 were excluded from the study because of a failure 
to come for follow-up visits or control examinations per-
formed in other diagnostic centers. Control USG was per-
formed by specialists from the Department of Radiology at 
the Army Hospital. Complications of the procedure inclu-
ded 4 cases of intraoperative profuse bleeding, for which 
additional pressure dressing was applied and which were 
treated with anti-hemorrhage drugs and remained for 24 
h under observation in the Oncologic Surgery Ward, and 
one case of uncontrolled skin cut, sutured and dressed in 
the Laboratory. Hematomas forming at the biopsy site were 
treated as a normal symptom. No cases of breast deforma-
tion were noted.
The mean age of the patients was 42.5 years (range 17–79). 
The tumor size ranged from 5 to 25 mm (mean 11.8 mm). 
Seventy two tumors were equal to, or smaller than 1 cm in 
diameter, and 83 were larger; 121 were located in the exter-
nal quadrants of the breasts, and 34 in the medial ones. As 
far as location of the tumors in relation to skin surface and 
thoracic wall was concerned, 15 lesions were located sub-
cutaneously, 99 at intermediate depth in the breast paren-
chyma and 41 adjacent to the thoracic wall.
Results
In the group of 72 who underwent mammotomy in 2002, 
on control USG performed after 6 months, 51 (70.8%) cases 
Figure 1.  Mammotome excision scheme. Figure 2.  Mammotome needle insertion.
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of complete lesion ramoval, 9 (12.5%) hematomas and 12 
(16.7%) residual lesions. After one year, USG assessment 
revealed, respectively 58 (80.6%) tumor-free cases, 5 (6.9%) 
hematomas and 9 (12.5%) residual tumor fragments. The 
diversity of results between the two control examinations 
led to resignation from the USG performed after 6 months 
in the group of patients treated in 2003–2004 who were 
followed up according to the following schedule: physical 
examination one month after the procedure and usg of the 
breast after 12 months [Tab. 1 i 2].
The analysis was extended to include the factors which 
could be potential reasons for failure to remove the lesions 
completely. They included: tumor size, peripheral (para-
fascial and subcutaneous) location in the mammary gland, 
quadrant localization and the person performing the proce-
dure. The assessed parameters demonstrated that the loca-
tion of the lesion in the breast, both with respect to depth 
and to the breast quadrant, as well as the operator, have no 
significant influence of the completeness of the procedure. 
The only parameter influencing the completeness of resec-
tion is the primary tumor size (Tab. 3, 4, 5, 6).
Discussion
Analysis of the first group of patients of 2002 demonstrated 
that it seems justifiable to resign from the first USG control 
after 6 months. The image obtained at that time seems to be 
dependent on the dimensions of the excised tumor site and 
possible increased bleeding during and after the procedure. 
These factors interfere with correct interpretation of the 
image, which often shows a hypoechogenic area with irreg-
ular contour (a developing hematoma), or a mixed echoge-
nicity area where the lesion residues are difficult to detect. 
After 12 months, the healing processes eliminate to a large 
extent, or even completely, the hematoma, and in the scar 
that forms at the resection site it is easier to  distinguish the 
residual lesion. Additionally, for persons with no experience 
in post-mammotomy image assessment, the view of the site 
after 6 months may give a false impression of a hyperpla-
stic lesion. 
Many physicians performing mammotome biopsies consi-
der the location of the tumor to be an important progno-
stic factor for complete resection. In very thin patients 
with dense, compact breast parenchyma, parasternal or 
Figure 3 A, B.  Biopsy specimens and mammotome result. 
A B
Table 2.  Results – 2003-2004 group.
TOTAL 83
HEMATOMA 5 6%
RESIDUAL LESION 8 9.7%
LESION ABSENT 70 84.3%
Table 1.  Results – 2002 group.
TOTAL
6 MONTHS 12 MONTHS
72 72
HEMATOMA 9 12.5% 5 6.9%
RESIDUAL LESION 12 16.7% 9 12.5%
LESION ABSENT 51 70.8% 58 80.6%
Table 3.  Results according to lesion depth.
LOCALIZATION TOTAL NO ABNORMALITIES HEMATOMA RESIDUAL LESION
SUBCUTANEOUS 15 11 (73.4%) 2 (13.3%) 2 (13.3%)
MEDIAL 99 84 (84.8%) 6 (6.1%) 9 (9.1%)
PARIETAL 41 29 (70.8%) 6 (14.6%) 6 (14.6%)
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 intercostal location of the tumor is regarded as difficult 
because of the risk of disrupting the thoracic wall integri-
ty. The situation is similar in case of subcutaneous lesions. 
However, the results of the analysis did not demonstrate 
significant influence of these localizations on the effect of 
complete resection. 
The assessment of the operator concerned the learning 
curve (more or less experience in the procedure). No sig-
nificant influence was noted in this case, either. For more 
detailed analysis, the number of procedures performed by 
particular physicians according to lesion sizes and locations 
should be considered.
The results presented above with respect to complete 
resections fall within the mean rates reported by nume-
rous publications. Nevertheless, reliable comparisons are 
impossible because of different times of control USG after 
the procedure. The authors of other publications did not 
assess any of the failure parameters mentioned in the 
paper, except for lesion size. However, the percentages of 
complete resections reported in all papers are, consistently 
with our results, lower in case of lesions exceeding 1 cm in 
diameter [9–15].
Conclusions
Treatment of fibroadenoma type lesions with mammotome 
biopsy is justifiable, because:
–  collecting a few specimens from a pathologic change does 
not solve the problem if it is left in place. Considering 
the fact that some fibroadenomas tend to grow, 
the ultimate effect of treatment is their complete resec-
tion, i.e.another invasive procedure,
–  the possibility of monitoring the course of mammotome 
biopsy by means of USG allows to remove the lesions 
completely and precisely,
–  the next surgical procedure may lead to breast deforma-
tion and bad cosmetic effect due to the post-operative 
scar,
–  the costs of invasive procedures are limited to one proce-
dure only,
–  some patients, despite the diagnosis of a benign lesion, 
want it to be removed because they are afraid of develo-
ping breast cancer,
–  excellent cosmetic effect and no breast deformation gua-
rantee complete satisfaction of both the patient and the 
physician,
–  simplicity of the procedure, short duration and possibility 
to perform it on ambulatory basis allows the patients to 
return to work and to their private life immediately,
–  the use of disposable equipment only guarantees complete 
safety with respect to HBV, HCV and HIV infections.
All the above conclusions confirm that mammotome biopsy 
is a safe, esthetic and quick procedure allowing complete 
resection of benign breast pathologies of fibroadenoma type 
up to 1 cm in diameter.
Table 4.  Results according to localization quadrants.
QUADRANTS TOTAL NO ABNORMALITIES HEMATOMA RESIDUAL LESION
LATERAL 121 93 (76.9%) 12 (9.9%) 16 (13.2%)
MEDIAL 34 31 (91.2%) 2 (5.9%) 1 (2.9%)
Table 5.  Results according to performing physician.
DOCTOR TOTAL NO ABNORMALITIES HEMATOMA RESIDUAL LESION
GP 104 (67.1%) 87 (83.7%) 7 (6.7%) 10 (9.6%)
JN 51 (32.9%) 41 (80.4%) 3 (5.9%) 7 (13.7%)
Table 6.  Results according to lesion diameter.
LESION SIZE TOTAL NO ABNORMALITIES HEMATOMA RESIDUAL LESION
≤ 10 mm 72 64 (88.8%) 4 (5.6%) 4 (5.6%)
> 10 mm 83 60 (72.3%) 10 (12%) 13 (15.7%)
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